International Society for Stem Cell Application (ISSCA) and Marmara University Launch Stem Cell and Regenerative Medicine Fellowship Program in Turkey
Participants in the program will have access to over 200 hours of valuable online content and hands-on laboratory practice in the state-of-the-art facilities at Marmara University and StemBio. Generally, the program will cover a series of topics related to the general principles of regenerative medicine, including:
- Stem cell biology;
- Evidence-based treatments; and
- Tissue engineering.
Hear from Certified and Established Industry Leaders
The Stem Cell and Regenerative Medicine Fellowship Program aims to provide attendees with the chance to meet, interact, and learn from ISSCA-certified doctors, scientists, experts, and Marmara University professors with in-depth expertise in the field. There will be seven days of in-person training and a comprehensive digital course offering practical experience in stem cell classifications and laboratory applications, with a high emphasis on Good Manufacturing Practice (GMP) guidelines.
Learn About the Best Stem-Cell Application Practices and Procedures in Clinical and Manufacturing Operations
By attending the program, participants should be able to gain valuable answers to the “how to” questions related to the practical applications of stem cell biology and regenerative medicine in research laboratories and manufacturing facilities. Attendees can expect to learn the following:
- How to culture stem cells;
- How to meet quality control standards;
- How to comply with cGMP functions;
- How to operate within the recommended clinical procedures;
- How to apply and implement the regulations for stem cell processing in a certified manufacturing facility; and
- How to apply clinical guidelines and regulatory policies when developing a GMP facility
Besides, the seven-day fellowship program will also offer participants resources to bolster their stem cell operations, including copies of presentations, procedural guidelines, and all forms and documentation related to a GMP facility.
Moreover, the Stem Cell and Regenerative Medicine Fellowship Program will cover a range of clinical procedures, including:
- Tissue processing;
- Isolation of mesenchymal stem cells;
- Culture, Expansion and cryopreservation; and
- Clinical Application of stem cells for wide-ranging indications: participants will get case books and complete protocols for about 30 indications.
Why Attend the Stem Cell and Regenerative Medicine Fellowship Program?
The program provides a learning experience for medical professionals and scientists who’d love to further their knowledge and skills in stem cells and regenerative medicine. Attendees will get the opportunity to learn from the top professionals in the field and gain practical hands-on experience in world-class laboratory facilities.
Here’s what Global Stem Cells Global’s CEO, Benito Novas, had to say: “We are delighted to hold the Stem Cells and Regenerative Medicine Fellowship Program, which is designed to provide participants with the opportunity to gain and further their knowledge in stem cell biology and tissue engineering. In addition, ISSCA’s partnership with Marmara University will ensure attendees have access to professors with deep knowledge in the field and practical training in stem cell and regenerative medicine.”
For more information on the Stem Cell and Regenerative Fellowship Program, visit the ISSCA website or contact Global Stem Cells Group.
About Marmara University
Marmara University is a leading research university nestled in Istanbul, Turkey. It’s a distinguished academic institution with high authority in scientific research and academic excellence, specifically in medicine. The university provides undergraduate, graduate, and doctorate degrees, as well as certificate programs. Marmara University also boasts state-of-the-art facilities and dedicated faculty that chronicle its dedication to giving scholars world-class learning experiences and contributing to the advancement of knowledge in wide-ranging fields.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Global Stem Cells Group announces participation in IV Jornadas de Actualización Medestética 2023
Global Stem Cells Group (GSCG), a leading provider of regenerative medicine solutions, is proud to announce its participation in the IV Jornadas de Actualización Medestética 2023 through the International Society for Stem Cell Association (ISSCA), its educational division and also with its line of Cellgenic Exosomes products.
The congress, which will take place on March 30th and 31st at Paseo La Plaza in Buenos Aires, Argentina, will provide a platform for ISSCA to share its knowledge and expertise in regenerative medicine with the Argentine medical community.
ISSCA is a multidisciplinary community of physicians and scientists whose mission is to advance the science, technology, and practice of regenerative medicine to treat disease and lessen human suffering. The organization has been at the forefront of promoting excellent and standardized regenerative medicine and will continue to participate in similar medical events such as this one.
The Global Stem Cells Group will also have a booth at the event to showcase its products, Cellgenic Exosomes, in its two presentations: “Cellgenic Lyophilized Exosomes” and “Cellgenic Flow Exosomes.” Additionally, it will provide guidance on how to use the products on patients.
As part of the program, ISSCA faculty members will be giving presentations and holding practical workshops to demonstrate the latest applications of regenerative medicine. The ISSCA program will cover all aspects of regenerative medicine including guidelines and clinical protocols.
“We are excited to take part in this congress and share our expertise, knowledge, and cellgenic exosome product line with the Argentine medical community,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA.
The IV Jornadas de Actualización Medestética 2023 will feature various ISSCA-certified doctors and experts as speakers, including:
Dr. Silvina Pastrana
Dr. Pastrana heads the ISSCA chapter in Argentina and serves as the medical center’s director. “Traditional, advanced, and cutting-edge anti-aging and rejuvenation medicine” will be her theme at this congress. Dr. Silvina will deliver a 40-minute summary of all the regenerative medicine and cell therapies that are now being used to postpone aging and enhance quality of life. therapies using NK cells, fluid and lyophilized exosomes, allogenic therapies, and autologous cells.
Dr. Andrea Lapeire
Dr. Lapeire is a doctor of aesthetic medicine with advanced degrees in environment, homotoxicology, biological medicine, and obesity. She will speak on alopecias: traditional and cutting-edge. Exosome Use and Biological Stimulation Fundamentals.
Prof. Dr. Julio Ferreira
Professor Ferreira is from Argentina and is a professional cosmetic surgery and aesthetic medicine expert. He is a university professor of medicine and is the president of the South American Academy of Aesthetic Surgery. He will cover regenerative therapies in rejuvenation and facial harmonization in his lecture.
Dr. Alfonso Ciancaglini
A specialist in Medical Clinic and regenerative medicine, Dr. Alfonsoi is a member of the International Society For Cellular Therapy Application and holds a certification from the Stem Cells Group. His presentation will discuss the use of regenerative medicine to treat venous ulcers.
Benito Novas
Benito Novas is the Head of Public Relations for the International Society for Stem Cell Application from the USA. He is the senior marketing consultant and founder of “Estética marketing INC” as an Author, he has authored several books among them: Su clinica este’tica. Lo que dicen sus pacientes” Marketing Digital en su Clinica Estetica” and “Marketing en Tiempos de Crisis” for more information on Novas you can check on www.benitonovas.com. In this congress. Benito Novas will be covering Digital Marketing in Cash-based practices.
ISSCA at Global Perspective.
ISSCA has been at the forefront of promoting excellent and standardized regenerative medicine. For more information and updates. visit us at https://www.issca.us/
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Global Stem Cells Group (GSCG) and International Society for Stem Cell Application (ISSCA) to Participate in Dubai Stem Cell Congress 2023
MIAMI, Florida, February 15, 2023 – Global Stem Cells Group (GSCG) and its educational division, the International Society for Stem Cell Application (ISSCA), are proud to announce their participation as sponsors and co-organizers of the Dubai Stem Cell Congress 2023. The congress, endorsed by the Hortman Stem Cell Laboratory, will take place on the 27th and 28th of February 2023 at the prestigious Waldorf Astoria on The Palm in Dubai.
The congress will bring together international experts in regenerative medicine and stem cell research from around the world to share their knowledge, experiences, and insights with the academic community and the general public. The event will also provide a platform for patients to share their success stories of stem cell therapy and how it has helped them overcome various life-threatening diseases.
“We are honored to welcome you to the first edition of the Dubai Stem Cell Congress 2023, which will host international experts in the field of Regenerative Medicine & Stem Cell Research from around the world,” said Dr. Fatma Alhashimi, Chairman of Dubai Stem Cell Congress. “We will be showcasing cutting-edge data, stem cell technologies, and advanced applications.”
GSCG will showcase its range of cellular products and equipment, including exosomes for topical and intravenous use, Mesenchymal Stem Cells (MSC), Bone Marrow Kit, PRP Kit, Fat Kit for obtaining Stromal Vascular Fraction (SVF), workstation, and laboratory equipment. ISSCA, on the other hand, will be represented with its training, congresses, conferences, and the fellowship in Cellular Therapies.
“Our mission is to make cellular therapies a reality for both doctors and patients, and we are happy to continue that mission by sharing our knowledge and showcasing our Cellgenic branded Cellular products and equipment at the congress,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for ISSCA.
With over 25 world-class international speakers, including ISSCA-certified speakers, the congress will feature a variety of panel discussions, lectures, and presentations on the latest innovative technologies in stem cell and regenerative medicine.
ISSCA-certified speakers and experts who will be presenting lectures at the congress include the following:
- Erdinç Civelek, a brain surgeon at Gaziosmanpaşa Taksim Hospital for Research and Education in Turkey.
- Dr. Serdar Kabataş, a brain surgeon at Gaziosmanpaşa Taksim Research and Education Hospital in Turkey.
- Abdulmajeed Hamadi, a consultant hematologist and pioneer in transplantation and stem cell therapy with an FRCP designation in Iraq.
- Salih Yildirim, the Director of Overseas Operations of ISSCA and a member of the Board of Directors of the Global Stem Cell Group and Director of International Operations.
- Benito Novas, the Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for the Application of Stem Cells in the USA.
Among the esteemed speakers at the event are:
Prof. Anil Dhawan, Dr. Frances Verter, Dr. Masayo Takahashi, Dr. Essam Abdelalim, Prof. Shuibing Chen, Prof. John E. Wagner, Mrs. Kim Petrella, Dr. Edward Guindi, Dr. Mazaiah Yaacob, Dr. Mohammed Moulay, Mr. Oliver Papavlassopoulos, Dr. Sean Ng, Dr. Chiara Cugno, Dr. Siti Aminah, Mr. Thomas Moss, Prof. Dr. Tim Schulz, Dr. Luis Saraiva, Mrs. Renata Mihályová, Dr. Srinivasan Periathiruvadi and Dr. Ahmed Foul.
For the first time in the UAE, patients will have the opportunity to share their success stories of stem cell therapy, including the story of Mahra, a UAE national and survivor of Thalassemia, and the world’s first cord blood patient, Matthew Farrow.
Stem cell therapy is the present and future of medicine and holds the “Hope That Brings Life” to many patients in need. The Dubai Stem Cell Congress 2023 is a landmark event that will bring together leading experts, patients, and members of the academic community to share their experiences and knowledge about stem cell therapy and its advancements.
To learn more about the Dubai Stem Cell Congress 2023 and to make a reservation, visit the https://dubaistemcellcongress.com/ website, email info@stemcellsgroup.com, or call +1 305 560 5337.
About Hortman Stem Cell Laboratory
Mr. Darius Curta Managing Director of Hortman Healthcare Investment – Hortman Stem Cell Laboratory is the first state-of-the-art laboratory within the field of Stem Cells and Regenerative Medicine, focused on providing top-notch cord blood banking solutions. Additionally, our institution will be facilitating the first ever clinical trials in stem cell research in UAE. Hortman Stem Cell Laboratory, located at Golden Mile, Palm Jumeirah, consists of GMP Laboratories & ISO Clean Rooms for stem cell isolation, culture & expansion. Such a facility enables us to provide a solid foundation for successfully establishing an awareness and understanding of stem cells within the Middle Eastern Region. Hortman is leading that charge at the forefront of the research community.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
ISSCA’s On-site Training in Portugal
MIAMI, Florida, January 23, 2023 – The Global Stem Cells Group (GSCG) announces its long-awaited hands-on training this March 9th, 10th & 11th, 2023
The GSCG, through its International Society for Stem Cell Application (ISSCA) division, is holding a personalized, hands-on training course at Regenera clinic, located in Oeiras, Lisboa, Portugal. Industry-leading instructors across the regenerative medicine field will lead this onsite training course. We believe this course is a Total Solution for clinics as ISSCA teams will teach and train doctors and caregivers on the recent advances in regenerative medicine and cellular-based treatments.
Lisboa’s First On-site Training
Benito Novas, CEO of Global Stem Cells Group and Vice President of ISSCA, notes that “regenerative medicine is the future of health and beauty industries as more research is conducted and products developed for doctors to offer a superior service.”
Benito adds, “the training course will take a highly visual format with global experts interacting with trainees and live patients used to teach about different stem cell reintegration and procedural techniques with locally available tools and facilities.
The Lisboa training is the first in the country to bring clinics into the fold of regenerative medicine and stem cell treatments. Regenera clinic will be the first to be ISSCA certified and apply cellular therapies and regenerative medicine. Dr. Roni Lara Moya will be appointed Portugal Chapter director on 9th March.
The course design considers the needs of local trainees using a thorough scheduling process. Initial consultations between the trainees and ISSCA will inform equipment and kits availability, materials, underlying costs, and any other needs to be met during the main event.
What is the On-site Training About?
The following are some of the areas the onsite-training course will focus on:
1. Learning from Experts
A panel of stem cell therapy and regenerative medicine experts will lead the one-on-one training sessions. Cell therapy, skin regeneration techniques, bone marrow extraction, tissue engineering, and many more applications of advanced technologies to advance personalized health will be practically illustrated.
2. Trainees-Centered Treatment Protocols
The training course is personalized to every doctor and clinician’s specialization and the illness they are targeting. For example, stem cell treatment sessions will include various reintegration methods based on patients’ medical history and condition. The trainees will also have a first-hand view of how technology pushes the boundaries of regenerative medicine from research to the derivation of cell lines and, as we are all working to the possible future of genetic alteration.
Local nurses and medical assistants will also have a chance to be part of the process by going through a fully skilled procedural session that improves their assistance to the doctors.
3. International Certification
As an acclaimed stakeholder in regenerative medicine and stem cell treatment, ISSCA offers globally recognized certification to doctors and practitioners, highlighting their fascinating journey in this highly demanded field. According to the appointed chapter director of Portugal, Dr. Roni Lara Moya- “the upcoming onsite training is one of its kind ever conducted in the country. Dr. Moya asserts that “the collaboration between ISSCA and Regenerative Biomedicine Regenerative Clinic stems from a growing demand for new technologies and cutting-edge treatments that support patients’ positive health outcomes.”
4. Trends in Regenerative & Stem Cell Treatment
The training will cover stem cell and regenerative medicine’s practical, legal, technical, and ethical aspects. Laws, technological developments, and ethical concerns will be a critical part of the training course.
All are welcome to share the fantastic excitement of stem cell science and its promising future.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Mesenchymal Stem Cells For Cardiovascular Diseases
Despite progress in cardiovascular research, cardiac pathology continues to be one of the most common causes of morbidity and mortality in the world. Stem cell-based therapy has been recognized as an innovative strategy for the repair, regeneration and functional recovery of the myocardium, hence, once the animal research stage has been overcome, most clinical trials aimed at evaluating the safety and effectiveness of regenerative medicine in cardiovascular diseases have focused on angina pectoris, myocardial infarction and chronic cardiomyopathy. Although the current evidence of benefit is not conclusive, the evidence in favor of favorable results is growing.
In some cases, stem cell therapy can provide an effective treatment or alternative for diseases or disorders for which there is no effective treatment. Because these cells are capable of dividing into a wide range of lineages and tissues, they can be used to treat various diseases by repairing, replacing, and regenerating tissues.
It is unclear how umbilical cord mesenchymal stem cells act on the heart, but previous studies have shown that they possess an anti-apoptotic effect. The induced cardiomyocytes can form discs interspersed with myocytes from the host cells, creating a functional syncytium that will help contract the heart. Mesenchymal stem cells can improve cardiac function and reduce damage caused by cardiovascular disease, since they stimulate endogenous repair mechanisms, the regulation of the immune response, tissue perfusion and the proliferation of the resident heart rate, thereby improving cardiac function and reducing damage severity.
Refractory angina
This syndrome, characterized by persistent angina despite standard medical treatment, is often not revascularized due to diffuse coronary lesions or severe comorbidities.
In 2017, a review included 13 clinical studies, with 1061 patients and 12 months of follow-up on average, indicating cell therapy has emerged as a tool for managing these patients. Although the available data are inconclusive, the authors conclude that stem cell-based therapy could be a viable addition to conventional treatment options for refractory angina, given the paucity of therapeutic alternatives.
There was a reduction in mortality at two years after a meta-analysis in 2018, involving 304 patients, showed improved exercise tolerance and reduced angina attack frequency at three, six and 12 months. An additional meta-analysis published in March 2019, involving 526 patients monitored for 14 months, showed that patients treated with stem cells had fewer serious adverse effects, fewer deaths, fewer angina attacks, and fewer antianginal medications than those treated with conventional management.
A third meta-analysis from 2019, with 269 patients and 15 months of follow-up on average, reports the following results: decreased all-cause mortality, decreased frequency of angina and increased exercise time, with no increase in adverse reactions.
Cardiomyopathy (ischemic and non-ischemic)
Despite optimal medical and surgical management, many patients with heart failure undergo long-term myocardial remodeling that does not allow them to restore their ventricular function. This is because current treatment protocols cannot reverse the loss of cardiomyocytes due to cardiomyopathy. Since inflammatory responses continue over time as a central mechanism in the development of heart failure, it was of interest to investigate the anti-inflammatory, antifibrotic, and immunomodulatory properties of stem cells in patients with ischemic and non-ischemic cardiomyopathy.
In a review of five clinical studies published between 2017 and 2018, including 605 patients, the authors conclude that cell therapy is safe, causes immunomodulatory effects, improves functional capacity, and adds clinical benefits to standard therapies. According to them, the results are promising, and further evidence strengthening is recommended.
Based on a meta-analysis published in May 2019, involving 20 investigations and 1418 patients evaluated for an average of 21 months, stem cells improved cardiac function indicators (LVEF and LVESV), walking distance, functional classification of heart failure, quality of life, and mortality as compared to controls. Hospitalizations and serious adverse events were not different from those in the control group.
In a recent review of 9 studies involving 612 patients with heart failure, improvement was found in clinical and paraclinical parameters, evaluated on average for 9 months. According to the authors, stem cells are an effective therapy for the treatment of heart failure, improving patient prognosis and ability to exercise.
Acute myocardial infarction (AMI)
The application of stem cells was associated with a significant increase in left ventricular ejection fraction (LVEF) and other variables indicative of improved ventricular function and modification of remodeling in patients with AMI receiving timely percutaneous coronary intervention (PCI) and conventional medication in different studies. Even coronary artery bypass grafting with stem cells offers greater benefits. A number of studies have also shown that intravenous administration could be a more efficient and effective method of treating the heart or coronary arteries than direct application, with logistic, safety, and cost advantages.
Stem cell therapy is evidenced to be a safe way to treat cardiovascular diseases, as it shows an anti-apoptotic effect, reduction of lesion size, improvement of cardiac function through regulation of the immune response, adequate tissue perfusion and activation of growth factors.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Corporate News / Blog
Atherosclerosis obliterans grade IV: Application of Autologous Stem Cells
Atherosclerosis is the most common form of arterial occlusive disease in adults. About 15 percent of adults over 55 years of age suffer from critical ischemia, the most severe form of this disease.
Due to the gradual aging of the population and the growing number of people in their third age group, a number of studies have been conducted in order to improve the prognosis of atherosclerosis obliterans and to find alternatives to the mutilation of the extremities. As a general rule, chronic ischemia of the lower limbs should be treated to alleviate symptoms, particularly pain, prevent disease progression, and reduce the rate of amputations. In most patients with critical ischemia, the main goal is to preserve the affected limb.
The development of regenerative medicine is closely linked to the development of new knowledge about embryonic and adult stem cells, as well as the regenerative and therapeutic potential of stem cell therapy. The use of adult stem cells in the treatment of peripheral artery diseases has been demonstrated as a therapeutic agent for inducing angiogenesis. Recent preclinical studies as well as the pioneering clinical studies indicate that bone marrow-derived mononuclear cells (MBMCs) can enhance tissue vascularization in ischemic limbs, with results similar to those obtained with peripheral blood stem cells supply.
Cuba presented the first studies carried out in 2004 at the Institute of Hematology of the “Enrique Cabrera” hospital in Havana City, which achieved encouraging clinical results and had very few adverse effects in recent years.
A progressive rise in the accumulated experience with stem cells was also observed in Pinar del Rio in 2005, as the first 10 cases were carried out. The rising ease of obtaining this type of cell has made research and applications with these cells advance rapidly with great expectations in terms of clinical application.
A study published by Dia-Diaz, et al. in the Journal of Medical Sciences of Pinar del Rio examined 296 patients with grade IV atherosclerosis obliterans between 2009 and 2019. During the study, autologous stem cells were injected intramuscularly from peripheral blood. Within four weeks, pain relief was observed, as well as an increase in the pain-free claudication distance. Angiography after treatment revealed collateral vessel formation. The limb was saved in 201 patients (68%), while 95 cases (32%) presented amputation criteria. Complications were not reported following the procedure.
The study demonstrated the effectiveness of the implantation of autologous stem cells obtained from peripheral blood, as well as the favorable evolution of patients, clinical improvement of rest pain, walking distance without claudication and ankle-brachial pressure index.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Corporate News / Blog
The emerging role of MSC-derived exosomes in Regenerative Medicine
In recent years, MSCs have been introduced as respectable candidates for regenerative medicine due to their pro-angiogenic, anti-apoptotic, and immunomodulatory attributes. A variety of human tissues can be used as a source of mesenchymal stem/stromal cells (MSCs), ranging from bone marrow (BM) to umbilical cord (UC). These cells are typically multipotent and can differentiate into a variety of cell types. MSCs have been studied extensively for potential applications in cardiomyopathy, neurodegenerative disorders, spinal cord injuries (SCI), kidney injuries, liver injuries, lung injuries, and even cancer. According to current research, MSC-derived extracellular vesicles (EVs) contribute to MSC-exerted therapeutic benefits.
As defined by the International Society for Extracellular Vesicles (ISEV), EVs are lipid bilayer particles secreted by cells that do not replicate. EVs can be categorised into three subclasses based on size and biogenesis procedures: surrounding exosomes (50-150 nm), microvesicles (MVs) (100-1000 nm), and apoptotic bodies (ApoBDs) (500-5000 nm). In order for exosomes to be produced, multiple steps must occur; endosomes must be created from the plasma membrane, intraluminal vesicles must be formed within multivesicular bodies by inward budding, the MVB must merge with the plasma membrane, and finally the internal vesicles must be released.
By transmitting their molecules, such as proteins, messenger RNA (mRNA), and microRNAs (miRNAs), MSC exosomes stimulate phenotypic changes and subsequently modify regenerative programs of target organs. A number of mechanisms are involved in phenotypic alterations, including prevention of apoptosis, cell proliferation, immunomodulatory reactions, attenuation of oxidative stress, and improving oxygen supply to recipient cells. By supporting mitochondrial transfer, MSC-exosomes can suppress inflammatory cytokine production and induce phenotype 2 alveolar macrophages (M2), leading to acute lung injury (ALI) rescue. It has been demonstrated that the transmission of miRNAs from MSC-exosomes to recipient cells is responsible for the restoration of damaged kidneys, hearts, livers, and brains
Various cells continuously form and secrete exosomes, including lymphocytes, platelets, mast cells, intestinal epithelium, dendritic cells, neoplastic cell lines, microglia, neurons, and MSCs. Studies have shown that exosomes play an important role in cell-to-cell communication as well as several physiological and pathological processes. Despite their inherent biological activities, exosomes have recently been introduced as encouraging drug carriers because of their small size, high biocompatibility, and ability to hold different therapeutic ingredients, including proteins, nucleic acids, and small molecules. There have been reports showing the usefulness of MSCs-exosomes for treating a variety of ailments, such as lung, kidney, liver, neurodegenerative, cardiac, and musculoskeletal diseases, as well as skin wounds in vivo.
As well as their remarkable therapeutic effects, MSC-EVs derived from diverse sources also possess a variety of physiological functions that may affect their therapeutic application. In a wide range of human disorders, MSC-exosomes are considered an effective alternative to whole-cell therapy because of their low immunogenicity and improved safety profile. Although MSC-exosome applications still face various challenges, their benefits and capabilities are attracting increasing interest.
To learn more about exosomes and their clinical applications or if you’re interested in boosting your clinical practice with exosomes, go to our website www.cellgenic.com
- Published in Corporate News / Blog
Global Stem Cells Group announces the opening of a new Stem Cell Center in Bandung, Indonesia
Miami, FL, December 12, 2022 – Global Stem Cells Group (GSCG) is pleased to announce the opening of a new Stem Cell Center in Bandung, Indonesia in partnership with the Dr. Yanti Aesthetic Clinic. This joint venture will be the second in the country as they already have another facility in the stunning City of Surabaya.
The New Global Stem Cell Group Facility is Expected to Transform the Regenerative Medicine Field
The GSCG’s new center in Bandung aims to increase awareness about the benefits of regenerative medicine. Its launch strengthened the relationship between GSCG and the Dr. Yanti Aesthetic Clinic. This new facility is expected to transform regenerative medicine in the following ways:
- Offering accessible stem cell therapy to Indonesians;
- Promoting regenerative medicine technology; and
- Inspiring other doctors and industry experts to explore regenerative medicine.
Top Government Officials Attended the Launch of the Global Stem Cell Group Office in Bandung
The launch of the new Global Stem Cell Group facility in Bandung was a remarkable event in the medical field. The Minister of Tourism was among the top officials that witnessed the launch. Furthermore, the office of the Vice President sent several representatives.
What the President of Global Stem Cell Group Has to Say
Benito Novas, the president of the GSCG, was among the top industry specialists that graced the launch of the company’s second facility in Indonesia. According to him, GSCG wants to make regenerative medicine readily available for patients worldwide. Likewise, the company is encouraging more doctors to adopt stem cell therapy’s clinical and aesthetic applications in their work.
Benito Novas said: “We are dedicated to making it possible for both doctors and patients in all parts of the world to experience the benefits of regenerative medicines. The company is expanding and establishing itself as a market leader.”
The Director of the Dr. Yanti Aesthetic Clinic Appreciates GSCG
Dr. Yanti Kushmiran, director of the DR. Yanti Aesthetic Clinic, is once again honored to be part of this step into the future of regenerative medicine with its second Stem Cell Center in Indonesia together with the leading company Global Stem Cells Group.
Regarding this new clinic, Dr. Yanti says “We are honored to be part of GSCG, which has a more than 10-year track record in the market and a strong international reputation and to open a second cell therapy and regenerative medicine center facility under the Stem Cell Center brand. We will be able to provide more services to our patients as a result of this new partnership.”
Another GSCG Clinic is Opening in Indonesia by January 2023
The Global Stem Cell Group will continue increasing patients’ access to advanced regenerative medicine. As a result, the company plans to open another branch in Jakarta, the Capital of Indonesia. GSCG and its partners plan to launch this third facility in January 2023.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
- Published in Press Releases
New advances in osteoarthritis therapy with stem cells
Osteoarthritis is a rheumatic pathology that damages the articular cartilage. By joining two bones through the joint capsule, the joints are able to move, providing us with functional autonomy. An inner fluid called synovial fluid is usually found within joints, which is produced by the synovial membrane. Articular cartilage covers the ends of the bones that form the joint. As a result of damage to this articular cartilage, pain, stiffness, and functional impairment occur. Osteoarthritis is the most common joint disorder, usually beginning between the ages of 40 and 50, affecting to some degree almost everyone over the age of 80. Typically, osteoarthritis affects the spine, shoulders, fingers, hips, knees, and toe joints.
Stem cell therapies have the potential to treat a broad spectrum of diseases. Whether it’s rhizarthrosis, diabetes, neurodegenerative diseases, spinal cord injuries, or heart disease. By utilizing stem cells, regenerative medicine is capable of repairing tissues in affected areas. The main difference between lipo gem therapy and other treatments for osteoarthritis is that lipogem therapy regenerates cartilage, avoids surgery and its sequelae, and improves the quality of life for patients.
The potential for medical treatments with stem cells and their by-products is currently very high. In the field of sports medicine and traumatology, one of the most outstanding advances has been made for the first time in decades recently: Spanish scientists have achieved a degree of tendon regeneration in 100% of injured patients, resulting in a decrease in pain and a return to sport within two months, and just six months after the trial was completed.
A research performed by the Institute of Regenerative Tissue Therapy (ITRT), published by the prestigious American Journal of Sports Medicine. Demonstrates how this therapy regenerates chronic lesions in the patellar tendon and opens up a new therapeutic option for this tissue, which was considered impossible to regenerate.
In most patients, fat tissue can be harvested minimally invasively (under local or general anesthesia), providing a highly viable MSC population regardless of donor age. Similar to MSCs derived from other tissues, adipose tissue-derived MSCs have regenerative potential. As osteoarthritis is a very common joint disease, and knee osteoarthritis is the most common form, it is necessary to review scientific literature on osteoarthritis treatments with stem cells, like lipogems.
Lipogems Therapy
Lipogems therapy is a novel procedure that enhances the body’s natural ability to heal itself through the innovative power of science and biotechnology. The Lipogems method involves injecting mesenchymal stem cells into the joints. Adipose-derived mesenchymal stem cells have enormous regenerative potential. They also have a regenerative capacity independent of their age. Even older individuals can benefit from this procedure.
Injection of mesenchymal stem cells into the knee, particularly in the early stages of osteoarthritis, can stop the process of inflammation and degeneration, especially in the less advanced stages of the disease. In addition to preventing progressive physical deterioration of the articular cartilage, this treatment contributes significantly to a patient’s well-being and prevents the installation of knee prostheses.
Patellar tendinopathy, physiotherapeutic treatment and stem cell therapy
Injuries to the patellar tendon that connects the kneecap to the tibia are known as patellar tendinopathy or patellar tendinitis. The patellar tendon works with the muscles in the front of the thigh to extend the knee so you can kick, run and jump. Athletes who perform frequent jumping in their sports, such as basketball and volleyball, are most likely to suffer from patellar tendonitis. However, people who don’t engage in jumping sports may develop patellar tendonitis. Patients with patellar tendinitis usually begin treatment with physical therapy to stretch and strengthen their knee muscles.
Strength training with eccentric resistance is one of the most common treatments for tendinopathies. Alternatively, it has been demonstrated that bone marrow-derived mesenchymal stem cells (MSCs) can regenerate injured patellar tendons. Within six months of treatment, it has been observed that the structure of this tissue – which is always difficult to treat – is restored, reaching a regeneration of 40% in all injured persons, with a gradual improvement that eventually becomes complete.
It has been found that traditional management methods, including isometric or eccentric exercises, shock wave therapy, and even surgery, are not effective. As part of a rehabilitation program in chronic patellar tendinopathy, autologous expanded bone marrow mesenchymal stem cells (BM-MSC) or leukocyte-poor platelet-rich plasma (Lp-PRP) may be effective in reducing pain and improving activity levels. Traditional management, which includes isometric or eccentric exercises, shock wave therapy, and even surgery, has limited success. A combination of autologous expanded bone marrow mesenchymal stem cells (BM-MSCs) and leukocyte-poor platelet-rich plasma (Lp-PRP) and rehabilitation may reduce pain and improve activity levels in active participants with chronic patellar tendinopathy.
To learn more about stem cells, cellular therapies and keep up to date with all the information about regenerative medicine and its advances, sign up for our international certification in regenerative medicine at www.issca.us
- Published in Corporate News / Blog
Regenerative Medicine – An Overview On Stem Cell Therapy
Stem cell therapy is a form of regenerative medicine designed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This phenomenon makes stem cell therapy a viable treatment option for a variety of medical conditions.
What is stem cell therapy?
The term stem cell therapy refers to any treatment involving the use of viable human stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells. By being able to differentiate into the specific cell types necessary for repairing diseased tissues, stem cells are the ideal solution for tissue and organ transplantation.
As stem cell-based therapies are complex, researchers often seek stable, safe, and readily available sources of stem cells that can differentiate into multiple lineages. As such, choosing stem cells with clinical applications in mind is of the utmost importance
The hierarchy of stem cells
In general, stem cells fall into three categories. In addition to self-renewal, all three share a unique ability to differentiate. However, stem cells do not exist in a homogeneous form, but rather in a developmental hierarchy. Among all stem cells, totipotent cells are the most basic and least developed. These cells are capable of developing into a complete embryo while forming the extraembryonic tissue at the same time. During the fertilization of the ovum, this unique property begins and ends when the embryo reaches the stage of four to eight cells.
As the cell divides further, it loses its totipotency property and becomes a pluripotent cell, capable of dividing into each of the three embryonic germ layers (ectoderm, mesoderm, and endoderm). These cells are referred to as “embryonic stem cells” and are isolated from the inner cell mass of the blastocyst after the embryo is destroyed.
The property of pluripotency is lost with successive divisions, resulting in a more limited differentiation capability in which the cells can only differentiate into limited types of cells related to their origins. “Adult stem cells” have this property, which helps maintain homeostasis throughout the organism’s lifespan. It is known that adult stem cells are present in most specialized tissue types of the body in a metabolically quiescent state, including bone marrow and oral and dental tissue.
According to many authors, adult stem cells are the gold standard for stem cell-based therapies. A number of trials involving adult stem cells have shown promising results, especially in the transplantation of hematopoietic stem cells.
Stem cell research for treating disease
In 2006, Shinya Yamanka achieved a scientific breakthrough in stem cell research by generating cells with the same properties as embryonic stem cells. In fully differentiated somatic cells, namely fibroblasts, four transcription factors were transiently over-expressed, including OCT4, SOX2, KLF4, and MYC. As a result of the discovery of these cells, stem cell research has been transformed ever since. Similar to embryonic stem cells, these cells are capable of dividing into any of the germ layers. As a result of the development of iPSC technology, disease identification and treatment have become more innovative. IPSCs are therefore promising as a source of pluripotent derived patient-matched cells that can be used for autologous transplants because they can be generated from the patient’s own cells.
It is believed that stem cells, due to their unique capacity to regenerate, may hold new potential for treating diseases such as diabetes and heart disease. Despite this, there remains much work to be done in the laboratory and clinic to determine how these cells can be used in regenerative or reparative medicine to treat diseases.
Studies of stem cells in the laboratory allow scientists to gain a better understanding of the cells’ essential properties as well as what makes them different from specialized cell types. Researchers are already using stem cells to test new drugs and develop model systems for studying normal development and identifying the causes of birth defects in the laboratory.
The study of stem cells continues to advance our understanding of the development of an organism from a single cell and of how healthy cells replace damaged cells in adult organisms. Research on stem cells is one of the most fascinating areas of contemporary biology, but, as with many fields of science that expand rapidly, it raises as many questions as it answers.
To learn more about stem cells, cellular therapies and new medical protocols using exosomes sign up for our international certification in regenerative medicine at www.issca.us
- Published in Corporate News / Blog
